sirna
approach
demonstr
promis
treat
viral
infect
anim
model
poor
deliveri
limit
clinic
applic
issu
cell
host
microb
beloor
et
al
report
nosetobrain
deliveri
viraltarget
sirna
cure
mice
west
nile
viru
enceph
potenti
implic
human
infect
west
nile
viru
wnv
envelop
positivestrand
rna
viru
flavivirida
famili
caus
signific
morbid
mortal
human
like
flavivirus
japanes
enceph
jev
zika
wnv
neurotrop
thu
major
individu
infect
remain
asymptomat
develop
febril
ill
subset
patient
viru
spread
brain
caus
enceph
often
result
neurolog
complic
death
world
health
organ
unfortun
current
approv
vaccin
antivir
drug
avail
prevent
andor
treatment
wnv
infect
human
rna
interfer
rnai
endogen
regulatori
mechan
gene
express
reli
product
dice
long
doublestrand
rna
dsrna
nt
fragment
base
pair
complementari
gene
sequenc
silenc
express
via
either
direct
mrna
cleavag
inhibit
translat
given
sequenc
specif
adapt
capabl
broad
target
small
interf
rna
sirna
mediat
gene
silenc
wide
pursu
therapeut
strategi
indic
ill
cancer
inflammatori
genet
disord
review
tatiparti
et
al
sirna
target
viral
genom
shown
promis
treat
variou
viral
infect
anim
model
howev
challeng
limit
deliveri
target
tissu
offtarget
effect
remain
address
approach
approv
treat
human
viral
infect
issu
cell
host
microb
beloor
et
al
report
sirna
target
conserv
region
within
envelop
gene
wnv
protect
wnvinfect
mice
encephalitisinduc
morbid
mortal
uniqu
nosetobrain
deliveri
sirna
enabl
use
chimer
peptid
specif
brain
target
make
approach
attract
therapeut
candid
treatment
wnv
enceph
potenti
implic
viral
infect
noninfecti
brain
patholog
replic
multipl
virus
shown
inhibit
sirna
target
either
viral
cellular
gene
cell
cultur
model
sirna
also
shown
promis
deliv
target
organ
anim
model
variou
viral
infect
figur
exampl
mous
model
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
macaqu
model
sever
acut
respiratori
syndrom
corona
viru
sarscov
intranas
andor
inhal
viraltarget
sirna
reduc
viral
replic
lung
patholog
bitko
et
al
li
et
al
differ
diseas
model
hydrodynam
transfect
sirna
target
hepat
b
hbv
c
hcv
virus
mous
liver
via
tail
vein
reduc
viral
replic
liver
infect
mice
maepa
et
al
mccaffrey
et
al
intraven
administr
sirna
shown
success
treat
hbv
hiv
variou
mous
model
maepa
et
al
swami
et
al
nevertheless
intraven
mode
sirna
deliveri
subject
major
challeng
includ
nonspecif
bind
serum
protein
degrad
nucleas
rapid
renal
filtrat
entrap
phagocyt
cross
vascular
barrier
tissu
penetr
tatiparti
et
al
except
anecdot
success
therapeut
util
system
deliv
sirna
treat
viral
infect
anim
model
thu
limit
sirna
deliveri
brain
treatment
viral
enceph
challeng
need
effect
cross
bloodbrain
barrier
bbb
variou
approach
util
brain
deliveri
sirna
noninfecti
diseas
model
variabl
success
overcom
challeng
previou
report
kumar
colleagu
design
chimer
peptid
compos
rabi
viru
glycoprotein
rvg
bind
acetylcholin
receptor
express
neuron
nonaarginin
facilit
noncoval
bind
peptid
sirna
kumar
et
al
intraven
administr
peptid
enabl
specif
deliveri
sirna
target
jev
brain
jevinfect
mice
follow
receptormedi
intern
sirna
neuron
cell
kumar
et
al
treatment
reduc
encephalitisinduc
mortal
infect
mice
given
earli
late
diseas
cours
kumar
et
al
increas
therapeut
potenti
sirna
treat
viral
enceph
current
paper
beloor
et
al
explor
intranas
deliveri
peptideteth
sirna
figur
uniqu
connect
brain
outsid
world
provid
olfactori
nerv
circumv
challeng
associ
cross
bbb
thu
nosetobrain
deliveri
modifi
neurotrop
therapeut
sirna
substanti
increas
sirna
bioavail
brain
rel
intraven
administr
allow
dose
reduct
beloor
et
al
sirna
deliv
via
rout
reveal
remark
therapeut
effect
reduc
brain
viral
load
neuropatholog
mortal
even
treatment
initi
late
stage
wnv
infect
beloor
et
al
addit
minim
system
distribut
sirna
treatment
allow
wnv
replic
outsid
brain
trigger
natur
protect
immun
respons
beloor
et
al
contribut
recoveri
primari
infect
offer
longterm
immun
beloor
et
al
furthermor
immun
could
pass
onto
naiv
mice
challeng
wnv
adopt
transfer
cell
sera
beloor
et
al
thought
provok
efficaci
mice
investig
requir
establish
translat
human
wnvmediat
diseas
treatment
first
effect
intranas
deliveri
treat
human
brain
patholog
limit
date
part
due
anatom
differ
result
reduc
absorpt
human
nasal
epithelium
miyak
bleier
effect
practic
novel
approach
design
increas
nasal
absorpt
nasal
mucosa
surgic
flap
studi
second
potenti
differ
therapeut
window
mice
human
empir
explor
third
sinc
diseas
burden
greater
olderimmunocompromis
peopl
clinic
util
approach
reduc
rather
abrog
viru
replic
similarli
need
establish
sever
addit
challeng
relev
advanc
therapeut
sirna
candid
clinic
also
address
offtarget
effect
obviou
concern
sinc
imperfect
base
pair
host
gene
disrupt
express
addit
high
concentr
therapeut
sirna
may
satur
endogen
rnai
machineri
bitko
et
al
thu
disrupt
normal
gene
regul
nevertheless
target
brain
deliveri
rel
low
therapeut
dose
facilit
peptid
approach
propos
beloor
et
al
may
reduc
risk
hand
introduct
peptidebas
deliveri
pose
potenti
immunogen
concern
well
predict
anim
model
sinc
sirna
activ
depend
high
sequenc
homolog
anoth
potenti
limit
translat
viraltarget
sirna
clinic
product
larg
heterogen
viral
sequenc
thu
valid
data
present
beloor
et
al
multipl
clinic
viral
isol
requir
better
estim
translat
util
moreov
target
viral
rna
singl
sirna
may
caus
select
sirnaresist
viru
therefor
import
determin
genet
barrier
resist
viraltarget
sirna
approach
vitro
anim
model
combin
sever
sirna
target
distinct
region
viral
genom
use
singl
sirna
combin
antivir
agent
potenti
strategi
increas
resist
barrier
cocktail
approach
may
also
allow
broadspectrum
coverag
combin
sirna
target
genom
sever
virus
andor
host
gene
essenti
life
cycl
multipl
unrel
virus
inde
mixtur
two
sirna
target
rsv
piv
effect
prevent
diseas
coinfect
mous
model
use
low
dose
bitko
et
al
broadspectrum
approach
particularli
advantag
rapid
accur
diagnosi
viral
agent
challeng
often
case
viral
enceph
nevertheless
care
evalu
dose
requir
ensur
efficaci
safeti
sirna
cocktail
given
challeng
best
knowledg
viraltarget
sirna
approach
advanc
clinic
trial
date
one
exampl
target
rsv
nucleocapsid
gene
intranas
deliveri
sirna
demonstr
safeti
toler
efficaci
prevent
rsv
infect
treat
infect
lung
transplant
recipi
sever
clinic
trial
phase
iiib
review
shahani
et
al
hbvtarget
sirna
also
evalu
clinic
maepa
et
al
advanc
compris
two
cholesterolconjug
sirna
hepatocytetarget
membranelyt
peptid
shown
safeti
efficaci
phase
clinic
trial
maepa
et
al
taken
togeth
sever
import
challeng
address
enabl
clinic
use
direct
nosetobrain
sirna
deliveri
may
find
util
treat
viral
enceph
possibl
noninfecti
diseas
involv
brain
human
